Zachary Roberts - Jan 25, 2024 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
EVP of R&D
Signature
/s/Earl Douglas, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Jan 25, 2024
Transactions value $
$0
Form type
4
Date filed
1/31/2024, 05:45 PM
Previous filing
Jan 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +140K +37.31% $0.00 515K Jan 25, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +495K $0.00 495K Jan 25, 2024 Common Stock 495K $3.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.